Letters to the Editor

Sussman S . The first asylums in Canada: A response to neglectful community care and current trends. Can J Psychiatry 1998;43:260–4.

Pokorny AD . Prediction of suicide in psychiatric patients: A report of a prospective study. Arch Gen Psychiatry 1983;40:294–7.

Cocozza J Steadman H . The failure of psychiatric predictions of dangerousness: Clear and convincing evidence. Rutgers Law Review 1976;29:1084–1101.

Kirk A . The prediction of violent behaviour during short-term civil commitment. Bull Am Acad Psychiatry Law 1989;17:345–53.

Murphy GE . Clinical identification of suicidal risk. Arch Gen Psychiatry 1972;27:356–9.

McNiel DE Binder RL . Predictive validity of judgements of dangerousness in emergency civil commitment. Am J Psychiatry 1987;144:197–200.

Rofman ES Askinazi C . The prediction of dangerous behavior in emergency civil commitment. Am J Psychiatry 1980;137:1061–4.

Yesavage JA Werner PD Becker JMT Mills MJ . Short-term civil commitment and the violent patient. Am J Psychiatry 1982;139:1145–9.

Ontario Ministry of Health. Implementation Planning Guidelines for Mental Health Reform. Toronto: Queen's Printer for Ontario; 1994.

Jacobsen FM . Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423–9.

Al-Mulhim A Atwal S Coupland NJ . Provocation of obsessive–compulsive behaviour and tremor by olanzapine [letter]. Can J Psychiatry 1998;43:645.

Mottard JP de la Sablonniere JF . Olanzapine-induced obsessive-compulsive disorder. Am J Psychiatry 1999;156:799–800.

Baker RW Ames D Umbricht DS Chengappa KN Schooler NR . Obsessive-compulsive symptoms in schizophrenia: A comparison of olanzapine and placebo. Psychopharmacol Bull 1996;32:89–93.

Weiss EL Potenza MN McDougle CJ Epperson CN . Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series. J Clin Psychiatry 1999;60:524–7.

Calabrese JR Kimmel SE Woyshville MJ Rapport DJ Faust CJ , Thompson PA, and others. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759–64.

Thompson J Chengappa KNR Good CB Baker RW Kiewe RP , Bezner J, and others. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria, proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13:95–8.

Chengappa KNR Pelucio M Baker RW Cole D . Recurrent pancreatitis on clozapine rechallenge. Journal of Psychopharmacology 1995;9:381–82.

Markowitz JS Grinberg R Jackson C . Marked liver enzyme elevations with clozapine. J Clin Psychopharmacol 1997;17:70–1.

Bandelow B Degner D Kreusch U Ruther E . Myocarditis under therapy with clozapine. Schizophr Res 1995;17:293–4.

Wickert WA Campbell NRC Martin L . Acute severe adverse clozapine reaction resembling systemic lupus erythematosus. Postgrad Med J 1994;70:940–1.

Benning TB . Clozapine-induced extrinsic allergic alveolitis. Br J Psychiatry 1998;173:440–1.

Catalano G Catalano MC Wetter RLF . Clozapine induced polyserositis. Clin Neuropharmacol 1997;20:352–6.

Koval MS Rames LJ Christie S . Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994;151:1520–1.

Stoppe G Muller P Fuchs T Ruther E . Life-threatening allergic reaction to clozapine. Br J Psychiatry 1992;161:259–61.

Hess DA Rieder MJ . The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 1997;31:1378–87.

Karagianis JL Phillips LC Hogan KP LeDrew KK . Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623–30.

Elias TJ Bannister KM Clarkson AR Faull D Faull RJ . Clozapine-induced acute interstitial nephritis [letter]. Lancet 1999;354:1180–1.

Pope HG Keck PE McElroy SL . Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227–33.

Walker AM Lanza LL Arellano F Rothman KJ . Mortality in current and former users of clozapine. Epidemiology 1997;8:671–7.

Clardy J Gale RH . Mortality risk and clozapine. Am J Psychiatry 1995;152:651.

Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43 Suppl 2:21S–40S.

O'Reilly RL . Is hospitalization bad for patients with psychiatric problems? [letter]. Can J Psychiatry 1999;44:709.

Kopala L Honer WG . Risperidone, serotonergic mechanisms, and obsessive–compulsive symptoms in schizophrenia. Am J Psychiatry 1994;151:1714–5.

Panagotis B Maria G Aris L . Development of obsessive and depressive symptoms during risperidone treatment. Br J Psychiatry 1999;174:559.

Biondi M Fedele L Arcangeli T . Development of obsessive–compulsive symptoms during clozapine treatment in schizophrenia and its positive response to clomipramine. Psychother Psychosom 1999;68:111–2.

Al-Mulhim A Atwal S . Provocation of obsessive–compulsive behaviour and tremor by olanzapine [letter]. Can J Psychiatry 1998;43:645.

Saxena S Wang D Bystritsky A Baxter LR Jr. , Risperidone augmentation of SRI treatment for refractory obsessive–compulsive disorder. J Clin Psychiatry 1996;57:303–6.

Agid O Lerer B . Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive–compulsive disorder without comorbid psychopathology. J Clin Psychiatry 1999;60:55–6.